Capital is flowing to the wrong point on the disease timeline
Kidney care has attracted more than $2.5 billion in investment capital over the past five years. The amount tells a clear story. Unfortunately, it may be the wrong one.
Investment has mostly concentrated on the disease at two points: early-stage, value-based care aimed at slowing chronic kidney disease progression for millions of Americans, and late-stage dialysis infrastructure serving the roughly 550,000 Americans already dependent on it. Both approaches are clinically and commercially important, but they miss what would have maximum impact.
That would be a third window, during an acute event when kidney function is vulnerable but still recoverable and that has been largely overlooked.
The value-based care signal
The Kidney Care Choices model, the federal government’s flagship kidney value-based care initiative, was evaluated by The Lewin Group in February 2026 on behalf of CMS. The findings showed measurable clinical improvements, including increased home dialysis adoption and improved living donor transplant rates. But on hospital spending, there was no statistically significant reduction. Net Medicare expenditures increased by approximately $305 million in the second performance year.
The dialysis equilibrium and the missing middle
At the other end of the spectrum, commercially-insured end stage renal disease patients incur first-year costs of roughly $238,000. Medicare spent approximately $49 billion on dialysis across 550,000 patients in 2019, the most recent comprehensive year available. Innovation in this space improves delivery and quality of life but operates largely after the highest-cost disease transition has already occurred. Dialysis is maintenance, not restoration.
Between early chronic disease management and end-stage renal disease lies a narrower, higher-leverage window.
Up to 30 percent of cardiac surgery patients have pre-existing CKD. For this population, acute stress events like surgery, heart failure and sepsis represent a critical moment in the patient’s life. Kidney function is vulnerable, but potentially still treatable.
The downstream economics of missing this window are substantial. CKD patients who experience acute kidney injury don’t simply recover and move on. What begins as a single ER visit can quickly escalate to five or six hospitalizations per year, with each visit more complicated than the last and the kidneys becoming increasingly depleted. The cumulative cost including dialysis initiation, accelerating readmissions, permanent loss of renal reserve is enormous relative to the cost of intervention during the acute window itself.
Emerging institutional accountability models are beginning to price this correctly. The TEAM model, which mandates participation for more than 700 hospitals across 188 markets, restructures financial accountability around five high volume surgical episodes, coronary artery bypass graft among them, from admission through 30 days after discharge. With that CKD burden carried into the OR, AKI is no longer an incidental complication. Under TEAM it is a direct institutional liability: every extended ICU stay, skilled nursing facility placement, readmission and dialysis initiation hits the margins. The economic incentive to intervene during the acute event has never been more precisely aligned with the clinical opportunity to do so.
The investment question
Kidney care may not have a capital shortage. It may have a placement problem. And the investors who recognize that the smartest investment is not during chronic management or dialysis infrastructure, but during the acute event in between may be best positioned to benefit from the emergence of Acute Renal Preservation as a distinct clinical and economic category.
Author Bio
